Merck spinout grabs some assets and launches a quest for the Holy Grail in antibiotics R&D
Terry Roemer did a lot more than clean out his desk when he decided to leave Merck after a 13-year career developing antibodies at the pharma giant. With R&D chief Roger Perlmutter’s blessings, he also gathered some preclinical programs to take with him that now form the pipeline at his new, upstart biotech based in Union, New Jersey. And he’s working with a small team of ex-Merck scientists ready to get things moving toward the clinic.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters